Sanofi invests $90M in Lantus plant in China
French drug major Sanofi-Aventis says it will invest $90.0 million to extend its current manufacturing facility located at the Beijing Economic and Technological Development Area, China, and to build pre-filled injection production lines for Lantus (insulin glargine) SoloSTAR.
With an expected capacity up to 50 million units, the new Lantus SoloSTAR investment will allow Sanofi to better meet the growth demand of the Chinese market and improve the standard-of-care to combat diabetes in this emerging market.
"The local production of Lantus SoloSTAR at the new manufacturing site is scheduled to start in 2012," said chief executive Chris Viehbacher.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze